

to provide advice to the Commissioner. The Oncologic Drugs Advisory Committee advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which the Food and Drug Administration has regulatory responsibility.

The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and makes appropriate recommendations to the Commissioner of Food and Drugs.

The Committee shall consist of a core of 13 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of general oncology, pediatric oncology, hematologic oncology, immunology oncology, biostatistics, and other related professions. Members will be invited to serve for overlapping terms of up to 4 years. Almost all non-Federal members of this committee serve as Special Government Employees. The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting member who is identified with industry interests.

Further information regarding the most recent charter and other information can be found at <http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm107395.htm> or by contacting the Designated Federal Officer (see **FOR FURTHER INFORMATION CONTACT**). In light of the fact that no change has been made to the committee name or description of duties, no amendment will be made to 21 CFR 14.100.

This document is issued under the Federal Advisory Committee Act (5 U.S.C. app.). For general information related to FDA advisory committees, please visit us at <http://www.fda.gov/AdvisoryCommittees/default.htm>.

Dated: September 1, 2016.

**Leslie Kux,**

*Associate Commissioner for Policy.*

[FR Doc. 2016-21550 Filed 9-7-16; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### National Advisory Council on the National Health Service Corps; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), notice is hereby given of the following meeting:

*Name:* National Advisory Council on the National Health Service Corps (NACNHSC).

*Dates and Times:* September 28, 2016 12:00 p.m.–3:30 p.m. EST.

*Place:* U.S. Department of Health and Human Services, Health Resources and Services Administration, 5600 Fishers Lane, Rockville, Maryland 20857, Conference Call Format.

*Status:* This advisory council meeting will be open to the public.

*Purpose:* The NACNHSC makes recommendations with respect to their responsibilities under Subpart II, Part D of Title III of the Public Health Service Act, as amended (National Health Service Corps and Health Professional Shortage Area Designations), and shall review and comment upon regulations promulgated by the Secretary under Subpart II.

*Agenda:* The NACNHSC has concluded its discussion for Fiscal Year 2016 and will present its formal recommendations for each priority area. The Council will discuss policy recommendations for the National Health Service Corps scholarship and loan repayment programs with respect to clinician recruitment and retention in underserved communities throughout the service areas of the NHSC, telehealth, Medication Assisted Treatment (MAT) certification, mentorship, and NHSC discipline expansion, specifically for mental and behavioral, and oral health providers.

The content of the agenda is subject to change prior to the meeting. The NACNHAC final agenda will be available 3 days in advance of the meeting at <http://nhsc.hrsa.gov/corpsexperience/aboutus/nationaladvisorycouncil/meetingsummaries/index.html>.

**SUPPLEMENTARY INFORMATION:** Further information regarding the NACNHSC, including the roster of members and past meetings summaries, is available at <http://nhsc.hrsa.gov/corpsexperience/aboutus/nationaladvisorycouncil/index.html>. Members of the public and interested parties may request to participate in the meeting by contacting

Monica-Tia Bullock via email at [MBullock@hrsa.gov](mailto:MBullock@hrsa.gov).

- The conference call-in number is 1-800-619-2521. Passcode: 9271697.

- The webinar link is <https://hrsa.connectsolutions.com/nacnhsc>.

Public participants may submit written statements in advance of the scheduled meeting. If you would like to provide oral public comment during the meeting please register with Monica-Tia Bullock at [MBullock@hrsa.gov](mailto:MBullock@hrsa.gov). Public comment will be limited to 3 minutes per speaker. Statements and comments can be addressed to Monica-Tia Bullock by emailing her at [MBullock@hrsa.gov](mailto:MBullock@hrsa.gov).

In addition, please be advised that committee members are given copies of all written statements submitted from the public. Any further public participation will be solely at the discretion of the Chair, with approval of the DFO. Registration through the designated contact for the public comment session is required. Individuals who need reasonable accommodations should contact Monica-Tia Bullock at least 10 days prior to the meeting.

#### FOR FURTHER INFORMATION CONTACT:

Anyone requesting information regarding the NACNHSC should contact CAPT Jeanean Willis-Marsh, Director, Division of National Health Service Corps, Bureau of Health Workforce, Health Resources and Services Administration, in one of three ways: (1) Send a request to the following address: CAPT Jeanean Willis-Marsh, Director, Division of National Health Service Corps, Bureau of Health Workforce, Health Resources and Services Administration, 5600 Fishers Lane, Room 14N108, Rockville, Maryland 20857; (2) call (301) 443-4494; or (3) send an email to [jwillis@hrsa.gov](mailto:jwillis@hrsa.gov).

**Jason E. Bennett,**

*Director, Division of the Executive Secretariat.*

[FR Doc. 2016-21581 Filed 9-7-16; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Delegation of Authorities

Notice is hereby given that I have delegated to the Commissioner of Food and Drugs (the Commissioner) the authorities vested in the Secretary of the Department of Health and Human Services under sections 102(b)(2), (c); 103(b), (c), (d), (h); 104; 105(b); 106(b), (c); 113(b); 114(d); 115; 201(c); 202(b); 204; 205(b)(2), (c); 206(b); 207(b); 304(b); 305; 306(b); 308; and 309 of the FDA

Food Safety Modernization Act (FSMA or the Act), which relate to the functions of the Food and Drug Administration.

This authority may be redelegated. This authority will be exercised in accordance with the Department of Health and Human Services applicable policies, procedures, guideline, and regulations.

I hereby ratify and affirm any actions taken the Commissioner, or the Commissioner's subordinates, that involved the exercise of the authority delegated herein prior to the effective date of this delegation.

This delegation is effective upon date of signature.

**Sylvia M. Burwell,**  
*Secretary.*

[FR Doc. 2016-21504 Filed 9-7-16; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Peer Review Meeting.

*Date:* October 5, 2016.

*Time:* 10:30 a.m. to 5:30 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, 4H200A/B, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Maryam Feili-Hariri, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/ NIAID, 5601 Fishers Lane, Rockville, MD 20852, 240-669-5026, [haririmf@niaid.nih.gov](mailto:haririmf@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: September 2, 2016.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-21616 Filed 9-7-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Cellular Signaling and Regulatory Systems Study Section, September 29, 2016, 08:00 a.m. to September 29, 2017, 06:00 p.m., Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814 which was published in the **Federal Register** on August 31, 2016, 81 FR PG 60010.

The end date is September 29, 2016 instead of September 29, 2017. The meeting location remains the same. The meeting is closed to the public.

Dated: September 1, 2016.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-21514 Filed 9-7-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Aging Special Emphasis Panel; Training Grants.

*Date:* October 18, 2016.

*Time:* 2:00 p.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2W200, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Jeannette L. Johnson, Ph.D., National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Suite 2W200, Bethesda, MD 20892, 301-402-7705, [JohnsonJ9@NIA.NIH.GOV](mailto:JohnsonJ9@NIA.NIH.GOV).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: September 1, 2016.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-21516 Filed 9-7-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Announcement of Requirements and Registration for "Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test" Challenge

*Authority:* 15 U.S.C. 3719.

**SUMMARY:** Through the "Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test" Challenge (the "Challenge"), the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR) are searching for novel and innovative *in vitro* diagnostic tests that would rapidly inform clinical treatment decisions and be of potential significant clinical and public health utility to combat the development and spread of antibiotic resistant bacteria. Tests of interest will provide novel, innovative solutions for use in inpatient and/or outpatient settings. The goal of the challenge is to identify a diagnostic test that when utilized would lead to more rapid clinical decision making such that antibiotic use and/or outcomes of patients infected with resistant pathogens are fundamentally improved compared to current standard of care, and/or reduce transmission of resistant pathogens such that population infection rates significantly decrease. The Challenge competition seeks to incentivize a broad range of scientists, engineers, and innovators to develop diagnostic tests that would enable health care providers to make more informed decisions on appropriate antibiotic use and infection prevention.

This Challenge, structured in three steps, will complement existing BARDA and NIH research portfolios by reaching